Vatican reports 35.5% increase in profit from holdings for 2024
The Vatican's central asset management agency, however, also said in an annual report that it had reassessed the total value of its holdings down to 2.6 billion euros from 2.74 billion euros, due to a reassessment of its real estate holdings.
The Administration of the Patrimony of the Holy See (APSA) said the reevaluation of its total holdings had taken several years and was partly based on fair value estimates from 2023.
Of the total 62.2 million euro profit reported for 2024, 38.1 million euros came through investments, said the statement.
The report said the agency had passed on 46.09 million euros for use in the Vatican's general budget, but would retain 16.1 million euros.
Leo, elected in May to replace the late Pope Francis, is facing both a Vatican budget shortfall and growing liabilities for the Vatican's pension fund.
Although the Vatican hasn't published a full budget report since 2022, accounts approved in mid-2024 included an 83-million-euro shortfall, two knowledgeable sources told Reuters.
The shortfall in the pension fund was estimated to total some 631 million euros by the Vatican's finance czar in 2022. There has been no official update to this figure, but several insiders have told Reuters they believe it has ballooned.
The Vatican maintains more than 5,400 real estate holdings worldwide, according to the new report. 4,234 of the holdings are in Italy, with 92% of those in the area around Rome, it said.
Another 1,200 Vatican real estate holdings are abroad, including in cities such as Paris, Geneva, Lausanne, and London, the report stated.
In 2024, the Vatican department reported a profit of 45.9 million euros for 2023.
The new report said the Vatican invests its portfolio "with the aim of diversifying investments and spreading out risk."
($1 = 0.8577 euros)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
11 minutes ago
- Reuters
Siemens reduces stake in Siemens Healthineers to 71.12%
MUNICH, July 31 (Reuters) - Siemens AG ( opens new tab reduced its stake in medical technology company Siemens Healthineers ( opens new tab by nearly 2 percentage points to 71.12%, according to a regulatory filing. Healthineers' CEO Bernd Montag said earlier this year that the company would welcome a stake reduction by its parent company, calling it "very good" for the long term. "We have repeatedly and clearly stated that we will reduce our stake in Siemens Healthineers as part of the acquisitions of Altair and Dotmatics, without prejudice to any strategic decisions," a Siemens spokesperson told Reuters on Thursday.
Reuters
11 minutes ago
- Reuters
AbbVie lifts annual profit forecast on strong demand for newer immunology drugs
July 31 (Reuters) - AbbVie (ABBV.N), opens new tab raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq. Shares of the drugmaker rose nearly 3% to $195.03 before the bell. The company is pushing Skyrizi and Rinvoq to counter the drop in sales of Humira, as the once-bestselling drug faces competition from several cheaper biosimilars that began hitting the U.S. market in 2023. "We're entering the second half of the year with substantial momentum," said CEO Robert Michael. Skyrizi recorded quarterly sales of $4.42 billion, beating analysts' average estimate of $4 billion, while Rinvoq sales of $2.03 billion surpassed estimates of $1.97 billion, according to data compiled by LSEG. The North Chicago-based drugmaker has spent more than $20 billion on acquisitions since 2023 as Humira lost patent protection. On Wednesday, Bloomberg News reported that AbbVie is in talks to acquire privately held psychiatric disorder drug developer Gilgamesh Pharmaceuticals in a deal worth about $1 billion. Global sales of arthritis treatment Humira, once the world's best-selling drug, came in at $1.18 billion in the second quarter, missing estimates of $1.45 billion. AbbVie's forecast raise comes on the back of the European Union's framework trade deal with the United States, under which all EU-produced pharmaceuticals entering the U.S. will be subject to a 15% tariff. AbbVie has a significant manufacturing presence in Ireland, where it makes its wrinkle treatment Botox. The company now expects adjusted annual profit per share between $11.88 and $12.08, compared with its previous expectations of $11.67 to $11.87. The company earned quarterly adjusted profit per share of $2.97, compared with estimates of $2.88.
Reuters
13 minutes ago
- Reuters
Aptiv forecasts better-than-expected 2025 profit despite auto tariffs hit
July 31 (Reuters) - Aptiv PLC forecast a bigger-than-expected annual adjusted profit on Thursday, banking on resilient demand for its auto parts despite pressure from U.S. tariffs and higher costs. U.S.-listed shares of the Dublin-based company rose nearly 3% in premarket trade. Strong demand from automakers for advanced driver-assistance features and infotainment systems has helped companies like Aptiv. But U.S. President Donald Trump's tariffs have hit the import-heavy automotive industry. Global demand for electric vehicles has also slowed down, forcing Aptiv to cut costs last year. Aptiv, which sources components globally for its auto parts business, counts major automakers such as the Detroit Three, Volkswagen AG ( opens new tab and BMW among its key clients. The supplier now expects annual adjusted earnings per share between $7.30 and $7.60, above analysts' estimates of $7.23, according to data compiled by LSEG. On an adjusted basis, Aptiv earned $2.12 per share in the quarter through June, compared with estimates of $1.84 per share. Overall quarterly net sales rose 3% to $5.2 billion from a year ago. Analysts on average expected net sales of $5.09 billion.
